<DOC>
	<DOC>NCT00995085</DOC>
	<brief_summary>This clinical study is designed to evaluate the safety and tolerability of a single oral administration of a Metadoxine slow release formulation to subjects diagnosed as having ADHD. Study also assess cognitive effects of such drug administration.</brief_summary>
	<brief_title>Efficacy Study of Metadoxine SR Formulation in Attention Deficit Hyperactivity Disorder (ADHD) Subjects</brief_title>
	<detailed_description>Primary outcome measure is the safety and tolerability of study drug after a single dosing. Additional outcomes include commission error rate from the TOVA test. The result is measured as standard score in % compared to the values of the normal population. Exploratory outcome measures include: 1. TOVA measures like response time , variability, omissions etc. 2. Subtests from Wechsler: digit memory, digit-number signs etc</detailed_description>
	<mesh_term>Attention Deficit Disorder with Hyperactivity</mesh_term>
	<mesh_term>Hyperkinesis</mesh_term>
	<mesh_term>Metadoxine</mesh_term>
	<mesh_term>Pyridoxine</mesh_term>
	<criteria>age 1845 diagnosed as ADHD PDD patients head injured patients patients suffering from heart, lung, liver, kidney, intestinal, endocrine an neurological diseases and patients who are sensitive to vitamin B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>June 2011</verification_date>
	<keyword>ADHD</keyword>
	<keyword>ADD</keyword>
	<keyword>TOVA</keyword>
	<keyword>METADOXINE</keyword>
</DOC>